Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.

Sausville, E A; Arbuck, S G; Messmann, R; Headlee, D; Bauer, K S; Lush, R M; Murgo, A; Figg, W D; Lahusen, T; Jaken, S; Jing , X; Roberge, M; Fuse, E; Kuwabara, T; Senderowicz, A M

Sausville, E A; Arbuck, S G; Messmann, R; Headlee, D; Bauer, K S; Lush, R M; Murgo, A; Figg, W D; Lahusen, T; Jaken, S; Jing , X; Roberge, M; Fuse, E; Kuwabara, T; Senderowicz, A M.

Affiliation

Sausville EA; Developmental Therapeutics Program Clinical Trials Unit, Medicine Branch, and Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20852, USA. Sausville@nih.gov

J Clin Oncol ; 19(8): 2319-33, 2001 Apr 15.

Article in En | MEDLINE | ID: mdl-11304786

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Alkaloids / Neoplasms / Antineoplastic Agents Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 2001 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Search on Google

Add to My VHL

XML

PubMed Links